Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Kerala Ayurveda's losses widen even as top line grows

Audited results for FY26 show standalone revenue up 17.6% but net loss deepening. The auditor flagged unprovided receivables from subsidiaries.

3 earlier stories on Kerala Ayurveda Ltd.
Mkt cap₹243 cr
ROE0.00%
Debt / eq.6.95
₹14.74 cr net loss FY26 standalone loss, up from ₹13.78 cr a year ago

What's new

  • Standalone revenue grew 17.6% to ₹85.48 cr but net loss widened to ₹14.74 cr.
  • Consolidated revenue rose 9% to ₹131.15 cr; consolidated net loss hit ₹20.65 cr.
  • Audit report includes an emphasis of matter on significant trade receivables from subsidiaries with no provision made.

Why this matters

Top-line growth without operating profit is the core problem. The wider loss despite a nearly 18% revenue jump means cost pressures are outpacing sales gains. The auditor's flag on unprovided subsidiary receivables adds a governance question to the financial one.

What we're watching

  • Whether the receivable issue triggers further scrutiny or a write-down.
  • Any management commentary on the path to profitability.
  • How the consolidated loss compares to prior-year consolidated figures.

The full read

Kerala Ayurveda grew revenue but kept losing money. Standalone sales for FY26 rose 17.6% to ₹85.48 crore, yet the net loss widened to ₹14.74 crore from ₹13.78 crore the year before. Consolidated results told the same story: 9% revenue growth to ₹131.15 crore against a deeper net loss of ₹20.65 crore. The audit report adds a governance wrinkle. It contains an emphasis of matter on significant trade receivables from subsidiaries with no provision made, meaning the company has not reserved against potential non-collection. This is a routine annual filing, but the numbers underline a persistent gap between growth and profitability.

Questions answered

Why did the net loss widen if revenue grew?
The filing shows revenue expanding 17.6% but costs rising faster, resulting in a net loss of ₹14.74 crore versus ₹13.78 crore the prior year. The numbers point to margin compression, not operational leverage.
What did the auditor flag in the report?
The audit report contains an emphasis of matter regarding significant outstanding trade receivables from subsidiaries for which no provision has been made. This means the company has not set aside money for potential non-collection of those amounts.
How did the consolidated business perform?
Consolidated revenue grew 9% to ₹131.15 crore, but the consolidated net loss was ₹20.65 crore. The pattern mirrors the standalone results: growth without profit.
Is this filing a routine annual disclosure?
Yes. This is the standard audited results filing for Q4 and full-year FY26 under SEBI regulations. The numbers were expected to be disseminated through normal market channels.
Mentioned: Kerala Ayurveda Ltd · ₹85.48 cr standalone revenue · ₹14.74 cr standalone net loss
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Kerala Ayurveda Ltd.

Pharmaceuticals
₹275 cr

Latest quarter · Dec 2025

Sales₹33 cr
Net profit−₹5 cr
Op. margin−4.6%
EPS−₹3.69

Strength & growth

Debt / equity6.95×
Current ratio0.46×
Sales CAGR+15.1%
  1. 25 May 2026 · 7:46 PM IST Kerala Ayurveda's losses widen even as top line grows
  2. 53d ago Kerala Ayurveda targets ₹200 cr revenue by FY27
  3. 53d ago Kerala Ayurveda's losses widened even as revenue grew
  4. 53d ago Kerala Ayurveda's losses widen even as revenue climbs